āļ„āļđāđˆāļĄāļ·āļ­āļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄ

AI āđāļĨāļ°āļāļēāļĢāļ•āļĢāļ§āļˆāđ€āļĨāļ·āļ­āļ”āđāļšāļšāļĨāļīāļāļ§āļīāļ”āļŠāļģāļŦāļĢāļąāļšāļĄāļ°āđ€āļĢāđ‡āļ‡

āļāļēāļĢāļ—āļ”āļŠāļ­āļšāđ€āļĨāļ·āļ­āļ”āđāļšāļšāļĨāļīāļāļ§āļīāļ”āļ—āļĩāđˆāđƒāļŠāđ‰ AI āļ§āļīāđ€āļ„āļĢāļēāļ°āļŦāđŒ DNA āļ—āļĩāđˆāđ„āļĄāđˆāļ•āļīāļ”āđ€āļ‹āļĨāļĨāđŒāđƒāļ™āļ•āļąāļ§āļ­āļĒāđˆāļēāļ‡āđ€āļĨāļ·āļ­āļ”āđ€āļžāļ·āđˆāļ­āļ„āđ‰āļ™āļŦāļēāļĢāļđāļ›āđāļšāļšāđ‚āļĄāđ€āļĨāļāļļāļĨāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡āļāļąāļšāļĄāļ°āđ€āļĢāđ‡āļ‡āļŦāļĨāļēāļĒāļŠāļ™āļīāļ”

āļŸāļąāļ‡āļ„āļģāđāļ™āļ°āļ™āļģāļ™āļĩāđ‰āļšāļĢāļĢāļĒāļēāļĒāđ‚āļ”āļĒ AI · ~3 min

āļšāļ™āļŦāļ™āđ‰āļēāļ™āļĩāđ‰āļ­āđˆāļēāļ™ 3 āļ™āļēāļ—āļĩ
  1. āļ āļēāļžāļĢāļ§āļĄ
  2. āđ€āļˆāļēāļ°āļĨāļķāļ
  3. āļāļēāļĢāđƒāļŠāđ‰āļ‡āļēāļ™āļˆāļĢāļīāļ‡āđƒāļ™āđ‚āļĨāļāđāļŦāđˆāļ‡āļ„āļ§āļēāļĄāđ€āļ›āđ‡āļ™āļˆāļĢāļīāļ‡
  4. The Future of AI and Liquid Biopsy for Cancer
  5. āļāļēāļĢāļ™āļģāđ„āļ›āļ›āļāļīāļšāļąāļ•āļī
  6. āļŠāļģāļĢāļ§āļˆāļ•āđˆāļ­āđ„āļ›
  7. āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

āļ āļēāļžāļĢāļ§āļĄ

They can produce a screening signal and predicted tissue origin, but a positive result needs diagnostic workup and a negative result does not rule out cancer.

āđ€āļˆāļēāļ°āļĨāļķāļ

A liquid biopsy uses blood-based material to look for signals associated with disease. In multi-cancer early detection research, cell-free DNA fragments are sequenced and machine-learning classifiers can evaluate methylation patterns that differ across tissues. A test may report whether a cancer signal was detected and predict a likely signal origin. This is a screening result, not a tissue diagnosis. A positive result needs a diagnostic workup chosen by qualified clinicians; a negative result cannot rule out cancer or replace established screening for breast, cervical, colorectal or other diseases. Clinical utility is a separate question from detecting a molecular signal. The randomized NHS-Galleri trial enrolled more than 142,000 adults and evaluated a blood test added to usual care. In May 2026, the trial team reported that its primary goal—a reduction in combined stage III and IV cancer diagnoses—was not met, although analyses found fewer stage IV diagnoses in later screening rounds. A separate performance paper published in September reported secondary test-performance endpoints across three annual rounds; these descriptive analyses do not establish that the test reduces cancer deaths. It also reported sensitivity for all cancers below 40% in the evaluated rounds, so many cancers were not detected by the test. The U.S. FDA reviewed a premarket application for Galleri at a September 2026 advisory meeting. An advisory committee vote is non-binding and is not the same as FDA authorization; the FDA presentation stated that no devices were then authorized for multi-cancer early-detection screening. Patients and clinicians should weigh false reassurance, false positives, follow-up procedures and uncertain mortality benefit. The technology is promising research, but a blood signal should not replace an exam, symptom evaluation or guideline-recommended screening.

āļāļēāļĢāđƒāļŠāđ‰āļ‡āļēāļ™āļˆāļĢāļīāļ‡āđƒāļ™āđ‚āļĨāļāđāļŦāđˆāļ‡āļ„āļ§āļēāļĄāđ€āļ›āđ‡āļ™āļˆāļĢāļīāļ‡

A clinician explains that a methylation-based blood test reports a cancer signal and a predicted origin, not a confirmed tumor.

A researcher compares a model’s sensitivity across early and later cancer stages before describing screening performance.

A person with a negative multi-cancer test continues guideline-recommended breast, cervical or colorectal screening.

A care team plans established imaging or biopsy after a positive signal rather than treating the blood result as pathology.

The Future of AI and Liquid Biopsy for Cancer

Further trial follow-up is needed to determine whether earlier signals change treatment, mortality, anxiety, health-service use or overall benefit. The NHS-Galleri investigators say mortality and resource outcomes remain under study. In the United States, an FDA advisory review occurred in September 2026, but advisory recommendations are non-binding and final authorization had not been announced at the time of the meeting materials. Future evaluation should test the entire diagnostic pathway, including false-positive workups and missed cancers, rather than only sequencing accuracy.

āļāļēāļĢāļ™āļģāđ„āļ›āļ›āļāļīāļšāļąāļ•āļī

āļ—āļģāđ„āļĄāļĄāļąāļ™āļ–āļķāļ‡āļŠāļģāļ„āļąāļ

  • āļšāļĢāļīāļšāļ—āđāļĨāļ°āļāļŽ. āļšāļĢāļīāļšāļ—āļ—āļēāļ‡āļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄāđ€āļ›āđ‡āļ™āļ•āļąāļ§āļāļģāļŦāļ™āļ”āļ§āđˆāļēāđāļ™āļ§āļ„āļīāļ” AI āļˆāļ°āļĢāļ­āļ”āļˆāļēāļāļāļēāļĢāļŠāļąāļĄāļœāļąāļŠāļāļąāļšāļ„āļ§āļēāļĄāđ€āļ›āđ‡āļ™āļˆāļĢāļīāļ‡āļŦāļĢāļ·āļ­āđ„āļĄāđˆ
  • āļāļēāļĢāļ„āļ§āļšāļ„āļļāļĄāļ„āļļāļ“āļ āļēāļž. āļ‚āđ‰āļ­āļˆāļģāļāļąāļ”āļ‚āļ­āļ‡āđ‚āļ”āđ€āļĄāļ™āļĄāļĩāļ­āļīāļ—āļ˜āļīāļžāļĨāļ•āđˆāļ­āļ­āļąāļ•āļĢāļēāļ‚āđ‰āļ­āļœāļīāļ”āļžāļĨāļēāļ”āļ—āļĩāđˆāļĒāļ­āļĄāļĢāļąāļšāđ„āļ”āđ‰āđāļĨāļ°āđāļšāļšāļˆāļģāļĨāļ­āļ‡āļāļēāļĢāļ„āļ§āļšāļ„āļļāļĄāļ”āļđāđāļĨ
  • āļŠāļĢāđ‰āļēāļ‡āļ—āļēāļ‡āđ€āļĨāļ·āļ­āļ. āļāļēāļĢāļ›āļĢāļąāļšāđƒāļŠāđ‰āļ—āļĩāđˆāļ›āļĢāļ°āļŠāļšāļ„āļ§āļēāļĄāļŠāļģāđ€āļĢāđ‡āļˆāļˆāļ°āļ›āļĢāļąāļšāļ„āļ§āļēāļĄāļŠāļēāļĄāļēāļĢāļ–āļ—āļēāļ‡āđ€āļ—āļ„āļ™āļīāļ„āđƒāļŦāđ‰āļŠāļ­āļ”āļ„āļĨāđ‰āļ­āļ‡āļāļąāļšāđ€āļ§āļīāļĢāđŒāļāđ‚āļŸāļĨāļ§āđŒāđāļ™āļ§āļŦāļ™āđ‰āļē

āļĢāļ°āļ§āļąāļ‡

  • āļ‚āđ‰āļ­āļāļģāļŦāļ™āļ”āļ”āđ‰āļēāļ™āļāļŽāļĢāļ°āđ€āļšāļĩāļĒāļšāļ­āļēāļˆāļ—āļģāđƒāļŦāđ‰āļ•āđ‰āļ™āđāļšāļšāļ—āļĩāđˆāđāļ‚āđ‡āļ‡āđāļāļĢāđˆāļ‡āđ€āļ›āđ‡āļ™āđ‚āļĄāļ†āļ°āđ„āļ”āđ‰
  • āļ‚āđ‰āļ­āļĄāļđāļĨāđƒāļ™āļ­āļ”āļĩāļ•āļ­āļēāļˆāđ€āļ‚āđ‰āļēāļĢāļŦāļąāļŠāļ­āļ„āļ•āļīāļ—āļĩāđˆāđ€āļ›āđ‡āļ™āļ­āļąāļ™āļ•āļĢāļēāļĒāļ•āđˆāļ­āļŠāļļāļĄāļŠāļ™āļšāļēāļ‡āđāļŦāđˆāļ‡
  • āļĢāļ°āļšāļšāđ€āļ”āļīāļĄāļŠāļēāļĄāļēāļĢāļ–āļŠāļĢāđ‰āļēāļ‡āļ›āļąāļāļŦāļēāļ„āļ­āļ‚āļ§āļ”āđƒāļ™āļāļēāļĢāļšāļđāļĢāļ“āļēāļāļēāļĢāđāļĨāļ°āļ•āđ‰āļ™āļ—āļļāļ™āđāļ­āļšāđāļāļ‡āđ„āļ”āđ‰

āļ‚āļąāđ‰āļ™āļ•āļ­āļ™āļ•āđˆāļ­āđ„āļ›

  1. āđƒāļŦāđ‰āļœāļđāđ‰āđ€āļŠāļĩāđˆāļĒāļ§āļŠāļēāļāđ‚āļ”āđ€āļĄāļ™āļĄāļĩāļŠāđˆāļ§āļ™āļĢāđˆāļ§āļĄāļ•āļąāđ‰āļ‡āđāļ•āđˆāļāļēāļĢāļāļģāļŦāļ™āļ”āļāļĢāļ­āļšāļ›āļąāļāļŦāļēāđ„āļ›āļˆāļ™āļ–āļķāļ‡āļāļēāļĢāļ›āļĢāļ°āđ€āļĄāļīāļ™
  2. āļ­āļ­āļāđāļšāļšāđ€āļŠāđ‰āļ™āļ—āļēāļ‡āļāļēāļĢāļ•āļĢāļ§āļˆāļŠāļ­āļšāđāļĨāļ°āđ€āļ­āļāļŠāļēāļĢāļ›āļĢāļ°āļāļ­āļšāļāđˆāļ­āļ™āļāļēāļĢāđ€āļ›āļīāļ”āļ•āļąāļ§
  3. āļ•āļĢāļ§āļˆāļŠāļ­āļšāļāļēāļĢāļ›āļāļīāļšāļąāļ•āļīāļ•āļēāļĄāļ‚āđ‰āļ­āļāļģāļŦāļ™āļ”āđāļĨāļ°āļ āļēāļĢāļ°āļœāļđāļāļžāļąāļ™āļ”āđ‰āļēāļ™āļ„āļ§āļēāļĄāļ›āļĨāļ­āļ”āļ āļąāļĒāļ•āļąāđ‰āļ‡āđāļ•āđˆāđ€āļ™āļīāđˆāļ™āđ†
  4. āđ€āļ›āļīāļ”āļ•āļąāļ§āđ€āļ›āđ‡āļ™āļĢāļ°āļĒāļ°āđ‚āļ”āļĒāļĄāļĩāđ€āļāļ“āļ‘āđŒāļāļēāļĢāļŦāļĒāļļāļ”āđāļĨāļ°āļĒāđ‰āļ­āļ™āļāļĨāļąāļšāļ—āļĩāđˆāļŠāļąāļ”āđ€āļˆāļ™

āļŠāļģāļĢāļ§āļˆāļ•āđˆāļ­āđ„āļ›

āļˆāļ”āļŦāļĄāļēāļĒāļ‚āđˆāļēāļ§āļŸāļĢāļĩ

āļĢāļąāļšāļŠāļĢāļļāļ› AI āļĢāļēāļĒāļ§āļąāļ™

āđ€āļĢāļ·āđˆāļ­āļ‡āļĢāļēāļ§ AI āļ—āļĩāđˆāļ•āļĢāļ§āļˆāļŠāļ­āļšāđāļĨāđ‰āļ§ 3 āđ€āļĢāļ·āđˆāļ­āļ‡āļ—āļļāļāļ§āļąāļ™āļ—āļģāļ‡āļēāļ™ āđ€āļŠāđ‰āļē, āđ€āļ‚āļĩāļĒāļ™āđ€āļ›āđ‡āļ™āļ āļēāļĐāļēāļ­āļąāļ‡āļāļĪāļĐāļ˜āļĢāļĢāļĄāļ”āļē āļŸāļĢāļĩāļ•āļĨāļ­āļ”āđ„āļ› āđ„āļĄāđˆāļĄāļĩāđ‚āļ†āļĐāļ“āļē

āļ­āļĩāđ€āļĄāļĨāļŦāļ™āļķāđˆāļ‡āļ‰āļšāļąāļšāļ—āļļāļāļ§āļąāļ™āļ—āļģāļ‡āļēāļ™ āļĒāļāđ€āļĨāļīāļāļāļēāļĢāļŠāļĄāļąāļ„āļĢāđƒāļ™āļ„āļĨāļīāļāđ€āļ”āļĩāļĒāļ§ āđ€āļĢāļēāđ„āļĄāđˆāđ€āļ„āļĒāļ‚āļēāļĒāļŦāļĢāļ·āļ­āđāļŠāļĢāđŒāļ—āļĩāđˆāļ­āļĒāļđāđˆāļ­āļĩāđ€āļĄāļĨāļ‚āļ­āļ‡āļ„āļļāļ“

āļ—āļ”āļŠāļ­āļšāļ•āļąāļ§āđ€āļ­āļ‡

Take the AI and Liquid Biopsy for Cancer quiz

āļ‚āđ‰āļ­āđ€āļŠāļ™āļ­āđāļ™āļ°āļ—āļąāļ™āļ—āļĩāļŠāļģāļŦāļĢāļąāļšāļ—āļļāļāļ„āļģāļ•āļ­āļš āđāļĨāļ°āđƒāļšāļĢāļąāļšāļĢāļ­āļ‡āļ—āļĩāđˆāļŠāļēāļĄāļēāļĢāļ–āđāļŠāļĢāđŒāđ„āļ”āđ‰āļžāļĢāđ‰āļ­āļĄ ID āļ—āļĩāđˆāļ•āļĢāļ§āļˆāļŠāļ­āļšāđ„āļ”āđ‰āđ€āļĄāļ·āđˆāļ­āļ„āļļāļ“āļœāđˆāļēāļ™āļŦāļĨāļąāļāļŠāļđāļ•āļĢ

āđ€āļĢāļīāđˆāļĄāđāļšāļšāļ—āļ”āļŠāļ­āļš

āļŠāļ™āļąāļšāļŠāļ™āļļāļ™āļāļēāļĢāļĻāļķāļāļĐāļē AI āļŸāļĢāļĩ AI Understanding āđ€āļ›āđ‡āļ™āļ­āļ‡āļ„āđŒāļāļĢāđ„āļĄāđˆāđāļŠāļ§āļ‡āļŦāļēāļœāļĨāļāļģāđ„āļĢ 501(c)(3) — āđ„āļĄāđˆāļĄāļĩāđ‚āļ†āļĐāļ“āļē āđ„āļĄāđˆāļĄāļĩāļāļģāđāļžāļ‡āđ€āļ‡āļīāļ™, āļ•āļĨāļ­āļ”āđ„āļ› āļšāļĢāļīāļˆāļēāļ„

āļ„āļģāļ–āļēāļĄāļ—āļĩāđˆāļžāļšāļšāđˆāļ­āļĒ

What is AI and Liquid Biopsy for Cancer?

AI-enabled liquid-biopsy tests analyze cell-free DNA in a blood sample for molecular patterns associated with multiple cancers. They can produce a screening signal and predicted tissue origin, but a positive result needs diagnostic workup and a negative result does not rule out cancer.

What molecular pattern does the Galleri test described by FDA analyze?

The FDA presentation describes sequencing methylation patterns in cell-free DNA from plasma.

What does a Cancer Signal Origin result represent?

The test predicts an origin for a detected signal, which then needs diagnostic workup.

What should follow a Cancer Signal Detected result?

FDA materials say a detected signal should be followed by clinical diagnostic workup.

How should someone interpret No Cancer Signal Detected?

FDA materials explicitly state a negative result does not rule out cancer.

What happened to the NHS-Galleri trial’s primary endpoint?

The trial’s primary endpoint of fewer combined stage III/IV diagnoses was not met.

āđ€āļĢāļĩāļĒāļ™āļĢāļđāđ‰āļ•āđˆāļ­āđ„āļ›

āļ„āļģāđāļ™āļ°āļ™āļģāļ—āļĩāđˆāđ€āļāļĩāđˆāļĒāļ§āļ‚āđ‰āļ­āļ‡

āļ„āļģāđāļ™āļ°āļ™āļģāđ€āļžāļīāđˆāļĄāđ€āļ•āļīāļĄāļ—āļĩāđˆāđ€āļĨāļ·āļ­āļāļŠāļģāļŦāļĢāļąāļšāļŦāļąāļ§āļ‚āđ‰āļ­āļ™āļĩāđ‰

āļ•āđˆāļ­āđ„āļ›āļ„āļģāđāļ™āļ°āļ™āļģāļ•āđˆāļ­āđ„āļ›

AI āđƒāļ™āļāļēāļĢāļ•āļĢāļ§āļˆāļ„āļąāļ”āļāļĢāļ­āļ‡āļĄāļ°āđ€āļĢāđ‡āļ‡āđ€āļ•āđ‰āļēāļ™āļĄ

āļ­āļļāļ•āļŠāļēāļŦāļāļĢāļĢāļĄ

āļĢāļąāļšāđƒāļšāļĢāļąāļšāļĢāļ­āļ‡ AI āļŸāļĢāļĩāļŦāļĨāļąāļāļŠāļđāļ•āļĢāđāļĨāļ°āļāļēāļĢāļŠāļ­āļšāļŠāļąāđ‰āļ™ āđ† āļŸāļĢāļĩ āđ„āļĄāđˆāļĄāļĩāļ„āđˆāļēāđƒāļŠāđ‰āļˆāđˆāļēāļĒ āđ„āļĄāđˆāļĄāļĩāļšāļąāļ•āļĢāđ€āļ„āļĢāļ”āļīāļ• āļ›āļĢāļ°āļĄāļēāļ“ 2.5 āļŠāļąāđˆāļ§āđ‚āļĄāļ‡āđ€āļĢāļīāđˆāļĄāļ•āđ‰āļ™āļŸāļĢāļĩ →